SCYNEXIS(US:SCYX) Newsfilterยท2025-04-08 12:00Core Insights - SCYNEXIS, Inc. announced the presentation of preclinical efficacy data for its second-generation fungerp candidate SCY-247 at the ESCMID Global conference in Vienna, focusing on its potential to treat systemic fungal diseases and drug-resistant infections [1][2]. Company Overview - SCYNEXIS is a biotechnology company dedicated to developing innovative medicines for difficult-to-treat infections, particularly those that are increasingly drug-resistant [13]. - The company is advancing its proprietary antifungal platform known as "fungerps," with SCY-247 being a key candidate in development [12][13]. Product Development - SCY-247 is designed to combat systemic fungal diseases, particularly invasive fungal infections where resistance to existing treatments is a major concern [2]. - The compound is a second-generation antifungal from a novel class of glucan synthase inhibitors, known as triterpenoids, which are the first new class of antifungal agents approved since 2001 [12]. - SCY-247 is currently in Phase 1 of development and has shown broad-spectrum antifungal activity against multidrug-resistant pathogens [12]. Preclinical Data - SCY-247 demonstrated potent antifungal activity against clinically relevant yeast species, including Candida auris and fluconazole-resistant Candida parapsilosis [4][6]. - In vitro studies showed that SCY-247 retained activity against a majority of antifungal-resistant Candida spp isolates, including those resistant to echinocandins [6][10]. - The compound exhibited robust in vitro activity against 65 Candida auris isolates, including strains with high resistance to echinocandins [8]. Future Prospects - SCYNEXIS anticipates that the U.S. FDA may grant SCY-247 Qualified Infectious Disease Product (QIDP) and Fast Track designations for both its IV and oral formulations [12].